What, Why, Where, and When: Bringing Timing to Immuno-Oncology

免疫疗法 医学 地铁列车时刻表 癌症免疫疗法 免疫系统 癌症 生物信息学 免疫学 计算生物学 生物 计算机科学 内科学 操作系统
作者
Adrienne M. Rothschilds,Karl Dane Wittrup
出处
期刊:Trends in Immunology [Elsevier BV]
卷期号:40 (1): 12-21 被引量:72
标识
DOI:10.1016/j.it.2018.11.003
摘要

The temporal progression of response to infection and the order of events in the cancer–immune cycle indicate the existence of an endogenous temporal program for the immune system. A growing number of examples illustrate that choice of dose schedule can either eliminate or synergistically amplify the therapeutic benefit of immunotherapeutic agents. Treatment schedule design should take into account both duration and sequencing of combination immunotherapy agents. New biomarkers such as circulating tumor DNA and cell counts derived from the blood can help align preclinical and clinical immunological timescales for clinical translation. A plethora of new cancer immunotherapies are under clinical development individually and in combination for a wide variety of indications, but optimizing therapeutic outcomes will require precise consideration of timing in treatment schedule design. In this review, we summarize the current understanding of the temporal rhythms of the anticancer immune response. Lessons learned in preclinical and clinical studies begin to define a framework for incorporating duration and sequencing into immunotherapy. We also discuss key challenges and opportunities for translation of temporally programmed treatment schedules to the clinic, including alignment of immunological timescales in preclinical models and humans, and the use of current and emerging biomarkers. A plethora of new cancer immunotherapies are under clinical development individually and in combination for a wide variety of indications, but optimizing therapeutic outcomes will require precise consideration of timing in treatment schedule design. In this review, we summarize the current understanding of the temporal rhythms of the anticancer immune response. Lessons learned in preclinical and clinical studies begin to define a framework for incorporating duration and sequencing into immunotherapy. We also discuss key challenges and opportunities for translation of temporally programmed treatment schedules to the clinic, including alignment of immunological timescales in preclinical models and humans, and the use of current and emerging biomarkers. costimulatory receptor expressed on the surface of a variety of cell types including T cells, NK cells, and DCs. cells such as DCs that take up antigens and are subsequently involved in priming and costimulation of T cells. antibodies that have two different target specificities because they have a different variable region on each of their two arms. a class of immunotherapy involving antagonizing receptors that stop or weaken lymphocyte activity (e.g., PD-1 and CTLA-4). DNA released from tumor cells found systemically, often identified by known tumor mutations. a harmful condition where the body produces excess inflammation in response to immunotherapy. a checkpoint receptor expressed on regulatory T cells and activated CD8+ and CD4+ effector T cells that blocks T cell costimulation. period of time for which a particular treatment is administered. process by which cancer escapes the immune system through soluble factors that suppress immune cells or cancer cell surface receptors that prevent immune recognition. an inflammatory cytokine with many functions including enhancing antibody-mediated cell killing and proliferation of lymphocytes. Ratio in the blood of neutrophils to lymphocytes. checkpoint receptor expressed on the surface of T cells that inhibits T cell activation. type of immune cells that restrain activation of the immune system. order in which individual agents in combination therapies are administered. group of receptors exerting related costimulatory effects on either APCs or T cells. Members of this family include 4-1BB (also known as CD137), OX40, CD40, and CD30. inflammatory cytokines such as IFNα with many functions including activation and maturation of APCs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
单薄冰安发布了新的文献求助10
1秒前
苗条的夜梦完成签到,获得积分10
2秒前
2秒前
搞怪建辉完成签到,获得积分10
2秒前
etheral完成签到 ,获得积分10
3秒前
鱼梓发布了新的文献求助10
3秒前
3秒前
4秒前
情怀的应助被Jacky采纳,获得10
4秒前
小燕尾条发布了新的文献求助10
4秒前
hjhhjh完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
风有约完成签到 ,获得积分10
7秒前
8秒前
踏实凡桃发布了新的文献求助10
8秒前
共享精神的应助被开心德地采纳,获得10
9秒前
打打的应助被整点可乐采纳,获得10
9秒前
9秒前
9秒前
10秒前
11秒前
CipherSage的应助被ke采纳,获得10
11秒前
19完成签到,获得积分10
12秒前
interguy发布了新的文献求助10
12秒前
14秒前
强强完成签到,获得积分10
15秒前
四十发布了新的文献求助10
15秒前
16秒前
17秒前
17秒前
18秒前
踏实凡桃完成签到,获得积分20
18秒前
贾贡献的应助被Dream采纳,获得10
21秒前
21秒前
21秒前
小马甲的应助被开心德地采纳,获得10
22秒前
洁净宝莹发布了新的文献求助10
22秒前
顺利的西瓜完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188654
求助须知:如何正确求助?哪些是违规求助? 9576372
关于积分的说明 21847161
捐赠科研通 7786741
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559632
邀请新用户注册赠送积分活动 2482360